to improve lives
The Brave Trial is designed to explore new developments in the treatment of DMD.
Advancing science to improve lives
Through meticulous research and compassionate care, the Brave Trial is designed to explore promising new developments in the treatment of DMD.
About the Trial
Brave is a clinical trial that will study the use of MNK-1411 as an experimental treatment for Duchenne muscular dystrophy.
A medication with a similar active ingredient is currently approved for the treatment of some inflammatory and autoimmune diseases outside of the U.S., but is not approved for and has never been studied in muscular dystrophy. MNK-1411 is an experimental alternative to treatment with glucocorticoids (e.g., prednisone or deflazacort).
TO QUALIFY FOR THE BRAVE CLINICAL TRIAL, PARTICIPANTS MUST:*
- Be between 4 and 8 years of age
- Have a documented diagnosis of DMD
- Subject has had previous systemic treatment with corticosteroids within 2 months prior to the Screening Visit.
- Have a legally authorized representative who can communicate with study personnel, be willing to follow all protocol procedures and agree to return for all required study visits
* For a complete description of study requirements, please contact us.
SCOPE OF THE TRIAL: A Commitment to Advancing Care
The study is designed to last for 24 weeks of a randomized, double-blind period, with the option for an additional open label extension period, if the initial 24-week period is completed, ensuring that all participants will have the opportunity to be treated with MNK-1411.
Total participation in the study includes:
- Screening period of up to 28 days
- Randomized double-blind period of 24 weeks
- Optional open-label extension period, for patients who complete the initial 24-week double-blind period
- Follow-up visit 28 days after final dosing
Each clinic visit expected to be an average of 4-6 hours.
Find a Trial Site
Brave Trial sites are located throughout North America, Latin America, Europe and the Middle East.